Search

The second edition of this book provides a completely updated account of the structure, dynamics, and physics of viral particles: from the moment they emerge by self-assembly from viral components produced in the infected cell, through their extracellular stage, until they recognize and infect a new host cell and cease to exist as they lose their physical integrity to initiate a new infectious cycle. New insights into the structure of viruses, their physical properties, and mechanisms of action, derived from results obtained in the last decade, have been included, as well as other (bio)physical techniques to study the structure or dynamics of virus particles and components. These include, among many others, new advances in high-resolution electron cryomicroscopy; novel approaches in the use of electron cryotomography or the application of soft X-ray tomography to study viruses in the infected cell; high-speed atomic force microscopy to study virus assembly and dynamics; and the development of new antiviral drugs and vaccines. as well as of many nanomedical and nanotechnological applications of virus particles. New chapters on the study of viruses inside infected cells and on technological applications of modified viral particles have been included in this second edition. The book is still aimed primarily at Master's students, Ph.D. students, and postdoctoral researchers with degrees in biology, chemistry, physics or related scientific disciplines who have an interest in or are working with viruses. It provides an up-to-date overview of many important concepts, techniques, studies and applications in structural and physical virology for specialized researchers working with viruses, regardless of their field of specialization, covering the latest research together with fundamental concepts and well-established facts. In short, this book is basic enough to be used by undergraduate and Ph.D. students, but advanced and up-to-date enough for experienced scientists with an interest in structural and/or physical virology.

KRAS Drug Discovery: Past, Present and Future is a comprehensive overview of the state-of-the-art medicinal chemistry approaches towards targeting the formerly undruggable oncogene, KRAS. It includes Seminal medicinal chemistry case histories of KRASG12C inhibitors such as Sotorosib, the first approved KRASG12C inhibitor for NSCLC, alongside the latest advances towards identification of in vivo tools and development candidates targeting KRAS G12D, KRAS G13C and other mutations. The book also provides the reader with a comprehensive overview of the in vitro assay systems, in vivo pharmacology xenograft models and chemical biology tools available to characterize small molecule inhibitors of KRAS. - Highlights key structure-based drug design (SBDD) innovations to generate potency and selectivity vs. KRAS - Analyzes medicinal chemistry case histories for seminal contributions to the KRAS field - Provides an overview of in vitro and in vivo methods for drugging KRAS

This book highlights key findings generated during the past years from the main disciplines that constitute Physical Virology, from theoretical physics and simulations to material sciences and vaccines development to structural biology. Each chapter is written by world-class scientists from these areas and is a comprehensive review of where this field stands, as well as the future of Physical Virology. The diversity in the formal training of these scientists results in solving common problems using very distinct approaches, which can produce surprising findings. The multi- and interdisciplinary nature of this field has created a remarkable community that aims at understanding how viruses work and how they can be used in material sciences, chemistry, and biomedicine. Furthermore, the development of Physical Virology has resulted in technological advances that have shaped other fields; for example, it would be impossible to think about the development of Cryo-EM to solve the structure of complex viruses with atomic resolution without the contribution of scientists that created the field of Physical Virology. In the past decade, there has been a great success in the generation of viral systems that can encapsulate drugs, non-viral genetic material, or nanoparticles, as well as in the chemical and genetical modification of virions. Without any doubt in the immediate future, some of these technologies will jump from the bench to the market, creating a revolution in translational and biomedical sciences. The book provides key perspectives for the field, derived from expert´s opinions.

Protein Homeostasis Diseases: Mechanisms and Novel Therapies offers an interdisciplinary examination of the fundamental aspects, biochemistry and molecular biology of protein homeostasis disease, including the use of natural and pharmacological small molecules to treat common and rare protein homeostasis disorders. Contributions from international experts discuss the biochemical and genetic components of protein homeostasis disorders, the mechanisms by which genetic variants may cause loss-of-function and gain-of-toxic-function, and how natural ligands can restore protein function and homeostasis in genetic diseases. Applied chapters provide guidance on employing high throughput sequencing and screening methodologies to develop pharmacological chaperones and repurpose approved drugs to treat protein homeostasis disorders. - Provides an interdisciplinary examination of protein homeostasis disorders, with an emphasis on treatment strategies employing small natural and pharmacological ligands - Offers applied approaches in employing high throughput sequencing and screening to develop pharmacological chaperones to treat protein homeostasis disease - Gathers expertise from a range of international chapter authors who work across various biological methods and disease specific disciplines of relevance

The book focuses on protein allostery in drug discovery. Allosteric regulation, ʹthe second secret of lifeʹ, fine-tunes virtually most biological processes and controls physiological activities. Allostery can both cause human diseases and contribute to development of new therapeutics. Allosteric drugs exhibit unparalleled advantages compared to conventional orthosteric drugs, rendering the development of allosteric modulators as an appealing strategy to improve selectivity and pharmacodynamic properties in drug leads. The Series delineates the immense significance of protein allostery—as demonstrated by recent advances in the repertoires of the concept, its mechanistic mechanisms, and networks, characteristics of allosteric proteins, modulators, and sites, development of computational and experimental methods to predict allosteric sites, small-molecule allosteric modulators of protein kinases and G-protein coupled receptors, engineering allostery, and the underlying role of allostery in precise medicine. Comprehensive understanding of protein allostery is expected to guide the rational design of allosteric drugs for the treatment of human diseases. The book would be useful for scientists and students in the field of protein science and Pharmacology etc.

Genomics in Precision Medicine makes the people aware about the field of genomics and that of precision medicine, by taking the readers through all the details related to genomics and precision medicine. It also updates the readers about the various innovations that have taken place in the field of precision medicine and discusses the path that is to be followed further. Also discussed in the book is a review on the relation between the precision medicine and the mutations that drive it, delving on the various computational methods and conformational principles for the detection of the factors that drive cancer. It also discusses the various genetic mutations and epigenetic modifications and goes on to explore the various benefits and harms in the research on precision medicine.

Unravelling the intricate cell signalling networks and their significance in cancer poses major intellectual challenge. Keeping this in mind, the book aims at understanding the mechanism of action of different proteins and their complexes in the cancer signalling pathways. Hence, the proposed book that comprises 20 chapters provides a comprehensive introduction on cell signalling, its alterations in cancer, molecules that have been popular targets as well as the ones that are emerging as targets. In addition, it discusses different forms of therapy that are coming up for its treatment. Other than that, a major portion of the book is focused on studying different disciplines at the interface of biology and other areas of science that are being used to understand cancer biology in depth.

THE COLLEGE BLUE BOOK is a comprehensive guide covering nearly 12,000 institutions of higher learning, occupational and technical schools, and distance learning programs. THE COLLEGE BLUE BOOK also features information on obtaining financial assistance for pursuing postsecondary education.

This book comprehensively reviews the state-of-the-art strategies developed for protein-protein interaction (PPI) inhibitors, and highlights the success stories in new drug discovery and development. Consisting of two parts with twelve chapters, it demonstrates the design strategies and case studies of small molecule PPI inhibitors. The first part discusses various discovery strategies for small molecule PPI inhibitors, such as high throughput screening, hot spot-based design, computational approaches, and fragment-based design. The second part presents recent advances in small molecule inhibitors, focusing on clinical candidates and new PPI targets. This book has broad appeal and is of significant interest to the pharmaceutical science and medicinal chemistry communities.

This volume focuses on virus-host cell interactions, cellular genes acquired or modulated by viruses, the pathological effects of these interactions, and therapeutic interventions. Several chapters specifically address the role of viruses and genes – such as oncogenes, proto-oncogenes, or tumor suppressor genes – in the etiology of human cancer. Oncogenic signaling by PI3 kinase, mTOR, Akt, or the major cancer drivers MYC and RAF, and the role of tumor suppressors like p53, are discussed in detail. The volume also explores the emerging role of noncoding RNAs such as microRNAs in tumorigenesis and cancer therapeutics, and offers new insights into the role of HIV-host interactions relevant to pathogenesis and treatment. Gathering contributions written by leading scientists in their respective fields, the volume offers a valuable resource for researchers and clinicians alike.

THE COLLEGE BLUE BOOK is a comprehensive guide covering nearly 12,000 institutions of higher learning, occupational and technical schools, and distance learning programs. THE COLLEGE BLUE BOOK also features information on obtaining financial assistance for pursuing postsecondary education.

This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.

THE COLLEGE BLUE BOOK is a comprehensive guide covering more than 11,800 institutions of higher learning, occupational and technical schools, and distance learning programs. THE COLLEGE BLUE BOOK also features information on obtaining financial assistance for pursuing postsecondary education.